Silver Book Fact

Over the past 15 years, three classes of drugs have reduced mortality and improved symptoms of heart failure in patients who have decreased heart muscle function. These classes of drugs are ACE inhibitors, beta adrenergic blocking agents, and aldosterone antagonists. They each decrease mortality per year by 10-40%, and the beneficial effects of each agent have appeared in large-scale clinical trials to be additive.

Weisfeldt M, Zeiman S. Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease. Health Aff. 2007; 26(1): 25-37. http://content.healthaffairs.org/cgi/content/full/26/1/25

Reference

Title
Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease
Publication
Health Aff
Publication Date
2007
Authors
Weisfeldt M, Zeiman S
Volume & Issue
Volume 26, Issue 1
Pages
25-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Between 1988 & 1994 and 1999 & 2004, use of pharmacological lipid-lowering treatment increased from 11.7% to 40.8%. Low-density lipoprotein cholesterol control increased from 4.0% to 25.1% among those with high…  
  • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
    An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.  
  • The development of antioxidants that reduce oxidative damage is underway. One antioxidant that has been found, uric acid, has an even greater protective effect when combined with tPA.  
  • Data from clinical trials demostrate that ICDs reduce sudden cardiac death 5-10% per year for 2-3 years, compared to antiarrhythmic drugs.  
  • Every $1 spent on technological innovations in heart attack care has produced an estimated $7 gain.